Published in Int J Cancer on March 16, 1998
DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PLoS One (2009) 0.91
Associated expression of α2,3sialylated type 2 chain structures with lymph node metastasis in distal colorectal cancer. Surg Today (2012) 0.76
Epithelial Expression of Human ABO Blood Group Genes Is Dependent upon a Downstream Regulatory Element Functioning through an Epithelial Cell-specific Transcription Factor, Elf5. J Biol Chem (2016) 0.75
ABO blood type and the risk of cancer - Findings from the Shanghai Cohort Study. PLoS One (2017) 0.75
Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int (2008) 6.04
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (2001) 4.99
Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science (1998) 4.24
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep (2000) 3.23
Tensile ductility and necking of metallic glass. Nat Mater (2007) 2.90
Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry (1988) 2.48
Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst (1998) 2.39
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region. Cancer (1998) 2.31
Primitive deuterostomes from the Chengjiang Lagerstätte (Lower Cambrian, China). Nature (2001) 2.31
Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev (1994) 2.26
Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst (1995) 2.25
The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol (1997) 2.13
Hyalinizing clear cell carcinoma of salivary gland. Am J Surg Pathol (1994) 2.12
Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg (1995) 2.06
Detection of Mycobacterium tuberculosis DNA in clinical samples by using a simple lysis method and polymerase chain reaction. J Clin Microbiol (1993) 1.96
p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res (1995) 1.95
Cystectomy for bladder cancer: a contemporary series. J Urol (2001) 1.85
A new species of yunnanozoan with implications for deuterostome evolution. Science (2003) 1.82
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol (1994) 1.78
Male urethral carcinoma: analysis of treatment outcome. Urology (1999) 1.77
Chewing tobacco, alcohol, and the risk of erythroplakia. Cancer Epidemiol Biomarkers Prev (2000) 1.76
Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg (1996) 1.74
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol (1995) 1.71
Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol (1995) 1.70
Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: a pilot study. J Urol (1999) 1.63
Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol Oncol (2000) 1.58
p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer (1994) 1.58
Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther (1999) 1.57
Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res (1999) 1.55
Papillary and follicular thyroid carcinomas with an insular component. Cancer (1994) 1.54
Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst (1994) 1.52
Protective effect of green tea on the risks of chronic gastritis and stomach cancer. Int J Cancer (2001) 1.43
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst (1993) 1.42
Smoking history and cancer patient survival: a hospital cancer registry study. Cancer Detect Prev (1997) 1.40
[Updating of prognostic factors in bladder carcinoma]. Med Clin (Barc) (1991) 1.39
[Developing a Clinical Performance Measures System for hemodialysis, Quality Group, Spanish Society of Nephrology]. Nefrologia (2007) 1.39
[Estimate of HIV-1 infection prevalence in pregnant women and effectiveness of zidovudine administered during pregnancy in the prevention of vertical transmission]. Med Clin (Barc) (2000) 1.39
Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res (1997) 1.35
Variants in KCNQ1 are associated with susceptibility to type 2 diabetes in the population of mainland China. Diabetologia (2009) 1.34
Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology (1996) 1.32
Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res (1995) 1.29
Molecular characterization of inherited medium-chain acyl-CoA dehydrogenase deficiency. Proc Natl Acad Sci U S A (1990) 1.28
Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc Natl Acad Sci U S A (1995) 1.26
GSTT1 and GSTM1 null genotypes and the risk of gastric cancer: a case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev (2000) 1.26
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol (1995) 1.26
Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst (1999) 1.25
Polymerase chain reaction for rapid diagnosis of tuberculous meningitis in AIDS patients. Neurology (1994) 1.24
Rapid diagnosis of Mycobacterium tuberculosis bacteremia by PCR. J Clin Microbiol (1996) 1.24
Glutathione S-transferases M1, T1 genotypes and the risk of gastric cancer: a case-control study. World J Gastroenterol (2001) 1.24
Biomineralization of carbonates by Halomonas eurihalina in solid and liquid media with different salinities: crystal formation sequence. Res Microbiol (1998) 1.23
Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant (1999) 1.23
p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. J Clin Oncol (1994) 1.22
Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab (1996) 1.22
Surgical management of Merkel cell carcinoma. Ann Surg (1999) 1.21
Positive association between variations in CDKAL1 and type 2 diabetes in Han Chinese individuals. Diabetologia (2008) 1.19
The role of dietary factors in the intestinal and diffuse histologic subtypes of gastric adenocarcinoma: a case-control study in the U.S. Cancer (1997) 1.17
Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) program. Am J Epidemiol (1995) 1.16
Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. Hum Pathol (1998) 1.15
Role of xanthine oxidase and reactive oxygen intermediates in LPS- and TNF-induced pulmonary edema. J Lab Clin Med (1994) 1.12
Synaptic defects and compensatory regulation of inositol metabolism in inositol polyphosphate 1-phosphatase mutants. Neuron (1998) 1.12
Inwardly rectifying K(+) channels in spermatogenic cells: functional expression and implication in sperm capacitation. Dev Biol (2001) 1.12
Gastric cardia cancer and dietary fiber. Gastroenterology (2001) 1.10
Bis(thiosemicarbazide-S,N)zinc(II) dinitrate. Acta Crystallogr C (2000) 1.10
Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol (1994) 1.10
Alcohol drinking, body mass index and the risk of oral leukoplakia in an Indian population. Int J Cancer (2000) 1.09
A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas. Oncogene (2009) 1.09
Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. J Urol (1996) 1.08
The stability of the metal complexes of cyclic tetra-aza tetra-acetic acids. Talanta (1992) 1.08
Socioeconomic status, lifestyle factors and oral premalignant lesions. Oral Oncol (2003) 1.08
Anthelminthic and antiallergic activities of Mangifera indica L. stem bark components Vimang and mangiferin. Phytother Res (2003) 1.07
Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol Biomarkers Prev (2001) 1.06
p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol (1998) 1.05
Long-term administration of green tea catechins prevents age-related spatial learning and memory decline in C57BL/6 J mice by regulating hippocampal cyclic amp-response element binding protein signaling cascade. Neuroscience (2009) 1.05
Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst (1996) 1.04
Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol (1999) 1.04
Tuberculosis: do we know enough? A study of patients and their families in an out-patient hospital setting in Karachi, Pakistan. Int J Tuberc Lung Dis (2003) 1.01
Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. Cancer Res (1998) 1.01
Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol (1994) 1.01
Evaluation of the in vitro antioxidant activity of Mangifera indica L. extract (Vimang). Phytother Res (2000) 1.00
Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am J Pathol (1996) 1.00
Leptomyxid amebic meningoencephalitis mimicking brain stem glioma. AJNR Am J Neuroradiol (1995) 0.99
Hexakis(antipyrine-O)terbium(III) triperchlorate. Acta Crystallogr C (2000) 0.97
Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors. Cancer Res (1996) 0.97
Precipitation of minerals by 22 species of moderately halophilic bacteria in artificial marine salts media: influence of salt concentration. Folia Microbiol (Praha) (2006) 0.96
Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol (1999) 0.96
Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma. Breast Cancer Res Treat (2001) 0.96
Evaluation of the genotoxic potential of Mangifera indica L. extract (Vimang), a new natural product with antioxidant activity. Food Chem Toxicol (2006) 0.96
Delays to treatment and out-of-pocket medical expenditure for tuberculosis patients, in an urban area of South America. Ann Trop Med Parasitol (2005) 0.96
Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res (1994) 0.96
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol (1995) 0.95
Isolation and characterization of the gene and cDNA encoding human mitochondrial creatine kinase. J Biol Chem (1989) 0.95
Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema: a multicenter trial. Chest (1996) 0.94